The FDA recently approved CD19-targeting CAR-T for the treatment of CD19 expressing B cell cancers, like acute lymphoblastic leukemia and non-Hodgkin lymphomas, as well as BCMA-targeted CAR-T for multiple myeloma (3, 4). This evidence concerns the gene CD19 and plasma cell myeloma.